Opinion

Video

Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure
March 30th 2025

ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure

Aislinn Antrim, Managing Editor
Introducing the Tell-Tale Heart Podcast
March 25th 2025

Introducing the Tell-Tale Heart Podcast

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement
March 29th 2025

ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement

Aislinn Antrim, Managing Editor
ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots
March 29th 2025

ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots

Aislinn Antrim, Managing Editor
ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer
March 29th 2025

ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer

Aislinn Antrim, Managing Editor
ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes
March 29th 2025

ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes

Aislinn Antrim, Managing Editor